Arbutus Biopharma Corp

Total Valuation

Arbutus Biopharma Corp carries a market capitalization of 837.99M, placing it among publicly traded companies globally. Its enterprise value stands at 856.53M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Arbutus Biopharma Corp currently has 197.63M shares outstanding.

Valuation Ratios

Arbutus Biopharma Corp trades at a trailing price-to-earnings ratio of 6.09. The price-to-sales ratio is 5.13, and the price-to-book ratio stands at 3.67.

Enterprise Valuation

The EV/Sales ratio of 4.71 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 5.81 provides insight into valuation relative to core operating earnings.

Financial Position

Arbutus Biopharma Corp maintains a current ratio of 81.42, meaning it holds 81.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.20, indicating conservative leverage, while an interest coverage ratio of 1,940.43 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Arbutus Biopharma Corp posts a return on equity of 89.58 and a return on invested capital of 85.89.

Stock Price Statistics

Arbutus Biopharma Corp's stock has declined approximately -7.03297% over the past 52 weeks. The 50-day moving average sits at 4.80, while the 200-day moving average is 4.52.

Income Statement

Over the trailing twelve months, Arbutus Biopharma Corp generated 181.72M in revenue and converted that into 153.05M in net income, yielding earnings per share of 0.79. EBITDA reached 147.47M, while operating income came in at 147.43M.

Balance Sheet

Arbutus Biopharma Corp holds 92.63M in cash and equivalents against 514,000.00 in total debt, resulting in a net debt position of -19.17M. Total book value stands at 258.73M, with working capital of 270.52M providing operational flexibility.

Cash Flow

Arbutus Biopharma Corp produced -24.62M in operating cash flow over the past twelve months.

Margins

Arbutus Biopharma Corp operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of 81.13 and net profit margin of 84.23 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Arbutus Biopharma Corp's most recent stock split took place on November 4, 2010 with a 5:1 split ratio.

Scores

Arbutus Biopharma Corp posts an Altman Z-Score of 34.63, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.